Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Copper Miners ETF (COPX) vs Enveric Biosciences Inc (ENVB) Price & Performance

Global X Copper Miners ETFTrade
Enveric Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Global X Copper Miners ETF vs Enveric Biosciences Inc — how do they compare? Global X Copper Miners ETF trades at $77.5, while Enveric Biosciences Inc trades at $1.32 (market cap $5.32M). The key difference: Global X Copper Miners ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.

COPXENVB
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$95.70$17.40
52-Week Low
$42.75$1.28
Market Cap
$5.32M
Enterprise Value
$408.82K

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Copper Miners ETF

COPX (Global X Copper Miners ETF) trades at $74.35, down 2.86% amid bearish technical signals with all 16 moving average indicators signaling sell. The ETF provides exposure to copper mining companies benefiting from AI-driven electrification demand, though key financial ratios remain undisclosed in current data. Recent news highlights copper's structural role in AI infrastructure and energy transition.

Outlook hinges on copper supply-demand dynamics amplified by AI data center expansion, though technical weakness suggests near-term pressure. Risks include commodity price volatility and execution challenges in mining supply chains. Analyst sentiment remains constructive on long-term copper fundamentals despite current bearish technical positioning.

Enveric Biosciences Inc

ENVB trades at $1.33, down 1.48% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company shows significant financial challenges with negative ROE of -257.95% and ROA of -218.01%, though it has consistently beaten earnings expectations in recent quarters. Recent news highlights active participation in investor conferences and progress with EB-003 drug candidate development.

While analyst consensus is 75% buy-rated, the stock faces substantial fundamental risks from negative profitability and cash burn. Investment opportunity exists if clinical developments succeed, but shareholders should weigh high operational losses against potential biotech breakthroughs in the neuroplastogenic therapeutics space.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X Copper Miners ETF

COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.

Read more on COPX

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB